Citadel Advisors
RUBY

Citadel Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Citadel Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-600
Closed -$103 – 16080
2022
Q4 		$103 Buy
+600
New +$164 ﹤0.01% 14760

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Citadel Advisors's RUBY Position: Q1 2023 in Review

Citadel Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 132,322 shares — an estimated $22.8K sold.

Citadel Advisors first reported a position in RUBY in Q2 2019 and held it in 13 quarters. The position peaked at $3.38M in Q2 2019. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Citadel Advisors reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 132,322 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $22.8K.
  • Citadel Advisors first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 13 quarters.
  • Citadel Advisors's Rubius Therapeutics, Inc position peaked at $3.38M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.